05.03.2019 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: Evonik more robust as strategy takes effect


 

DGAP-News: Evonik Industries AG / Key word(s): Annual Results
Evonik Industries AG: Evonik more robust as strategy takes effect

05.03.2019 / 07:00
The issuer is solely responsible for the content of this announcement.


Key Financial Data: January 1 to December 31, 2018

Evonik more robust as strategy takes effect

- Promised and delivered: adjusted EBITDA climbs to EUR2.6 billion

- Sales rise 4 percent to EUR15 billion

- Outlook for 2019: adjusted EBITDA to decline slightly or to remain stable, free cash flow to rise significantly

Essen, Germany. Evonik grew again strongly in 2018. Adjusted EBITDA increased 10 percent to EUR2.6 billion, compared with the previous year. All three chemical segments contributed to profit growth. The earnings forecast, that Evonik had raised after the first half of the year, was achieved despite external adversities in the second half of the year.

Sales rose 4 percent to EUR15 billion. The adjusted EBITDA margin climbed to 17.3 percent, about 1 percentage point higher than in 2017, taking Evonik a significant step towards its mid-term goal of earning a margin between 18 percent and 20 percent.

"Despite substantial external burdens, we delivered on our forecast for 2018," said Christian Kullmann, chairman of the executive board of Evonik. "The consistent implementation of our strategy has shown Evonik to be more robust, even in times of a weaker global economy and unusual weather patterns."

At the annual shareholders' meeting on May 28, the executive board and supervisory board will be proposing a dividend of EUR1.15 per share. Based on the closing share price at year-end 2018 that gives a dividend yield of 5.3 percent, positioning Evonik among the top chemical companies.

Adjusted net income for the year rose 29 percent to EUR1.29 billion, reaching a record level. Evonik generated free cash flow of EUR672 million.

"We promised a considerably higher free cash flow for 2018 and we have delivered," Chief Financial Officer Ute Wolf said. "This year we will continue to work on steadily improving our free cash flow."

As announced in fall 2017, Evonik is optimizing its administrative and sales processes to permanently reduce costs by EUR200 million a year by the end of 2020. Savings of EUR50 million are already reflected in 2018 earnings and measures to achieve the remaining EUR150 million were identified during the course of last year.

With a new sustainability strategy 2020+, Evonik has set itself the goal of reducing its greenhouse gas emissions by 50 percent by 2025, using 2008 as a reference year. An internal price for CO2 will be taken into account for important investment decisions. At the same time, Evonik is expanding activities that will increase the share of products and solutions that have particular sustainability benefits. The company already generates about half of its sales from applications that have a proven contribution to improve resource efficiency for the customer.

Despite political uncertainties and weaker economic growth Evonik expects adjusted EBITDA in 2019 to be at about the level of 2018 or slightly lower.

"With the active honing of our portfolio and the sharpening of our cost awareness, Evonik is now in better shape to continue to drive transformation this year," said Kullmann. "It's not going to be an easy year but we are prepared to meet the challenges and will continue to build a best-in-class specialty chemicals company."

Segment performance

Resource Efficiency: Sales at the segment rose 6 percent to EUR5.71 billion in 2018. The main driver was higher selling prices, partly due to the passing on of higher raw-materials costs, and the inclusion of the silica business of J.M. Huber, acquired in September 2017. Demand for coating additives as well as for polyamide 12 from the auto and 3D-printing industries boosted sales at the segment. Adjusted EBITDA at Resource Efficiency increased 10 percent to EUR1.29 billion.

Nutrition & Care: Annual sales at the segment rose 3 percent to EUR4.65 billion as rising demand worldwide led to higher volumes and selling prices. Polymers for smart drug delivery systems in pharmaceutical applications were very successful at the healthcare business as were ingredients for personal care products. Although prices for essential amino acids for feed additives were below the previous year, sales remained stable because of higher volumes sold. The segment's adjusted EBITDA rose 8 percent to EUR810 million.

Performance Materials: Sales for the year rose 6 percent to EUR3.98 billion at Performance Materials, mainly because of significantly higher selling prices. The methacrylates business developed very well on continuing good demand, especially from the coatings and auto industries, as well as tight market supply. In the second half of the year low water levels in the Rhine River limited the transport of raw materials and goods and led to higher logistics costs. Adjusted EBITDA at the segment increased 2 percent to EUR670 million.

 




 

About Evonik
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of EUR15 billion and an operating profit (adjusted EBITDA) of EUR2.6 billion.

Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.




Contact:
Tim Lange
Head of Investor Relations
+49 201 177-3150
[email protected]

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Dr. Werner Müller, Honorary Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel
Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474


 


05.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: [email protected]
Internet: www.evonik.com
ISIN: DE000EVNK013
WKN: EVNK01
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange

 
End of News DGAP News Service

783719  05.03.2019 

fncls.ssp?fn=show_t_gif&application_id=783719&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 14.419,00 15.024,00 13.108,00 12.199,00 14.955,00 18.488,00 15.267,00
EBITDA1,2 2.357,00 2.150,00 2.153,00 1.837,00 2.246,00 2.510,00 1.598,00
EBITDA-Marge3 16,35 14,31 16,43 15,06 15,02 13,58
EBIT1,4 1.229,00 1.367,00 1.080,00 819,00 1.173,00 942,00 -243,00
EBIT-Marge5 8,52 9,10 8,24 6,71 7,84 5,10 -1,59
Jahresüberschuss1 734,00 954,00 2.127,00 479,00 767,00 555,00 -452,00
Netto-Marge6 5,09 6,35 16,23 3,93 5,13 3,00 -2,96
Cashflow1,7 1.551,00 1.704,00 1.321,00 1.727,00 1.815,00 1.650,00 1.594,00
Ergebnis je Aktie8 1,54 2,00 4,52 1,00 1,60 1,16 -1,00
Dividende8 1,15 1,15 1,15 1,15 1,17 1,17 1,15
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 18,445 Halten 8.595,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,19 15,91 0,88 11,42
KBV KCV KUV EV/EBITDA
1,03 5,39 0,56 7,45
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,17 1,17 6,34 04.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 01.08.2024 06.11.2024 04.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
6,42% 4,99% -0,30% -2,23%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei EQS abrufen


Chemie , EVNK01 , EVK , XETR:EVK